Eric F. Johnson

发表

P. Hajduk, J. T. Metz, Eric F. Johnson, 2011, Nature chemical biology.

D. Rees, Eric F. Johnson, O. Lewinson, 2009, Nature Reviews Molecular Cell Biology.

Permanent draft genome sequence of Desulfurococcus mobilis type strain DSM 2161, a thermoacidophilic sulfur-reducing crenarchaeon isolated from acidic hot springs of Hveravellir, Iceland

Natalia N. Ivanova, N. Kyrpides, V. Markowitz, 2016, Standards in Genomic Sciences.

Permanent Draft Genome Sequence of Desulfurococcus amylolyticus Strain Z-533T, a Peptide and Starch Degrader Isolated from Thermal Springs in the Kamchatka Peninsula and Kunashir Island, Russia

Natalia N. Ivanova, N. Kyrpides, A. Lapidus, 2017, Genome Announcements.

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

C. Tse, S. Fesik, Eric F. Johnson, 2008, Cancer research.

Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors

Yan Shi, S. C. Panchal, Eric F. Johnson, 2015, Molecular Cancer Research.

Structure of Human Microsomal Cytochrome P450 2C8

C David Stout, Eric F. Johnson, C. Stout, 2004, Journal of Biological Chemistry.

Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen

C David Stout, Eric F. Johnson, C. Stout, 2005, Nature Structural &Molecular Biology.

Adaptations for the Oxidation of Polycyclic Aromatic Hydrocarbons Exhibited by the Structure of Human P450 1A2*♦

C David Stout, Eric F. Johnson, C. Stout, 2007, Journal of Biological Chemistry.

Contributions of Ionic Interactions and Protein Dynamics to Cytochrome P450 2D6 (CYP2D6) Substrate and Inhibitor Binding*

Eric F. Johnson, C. Stout, Qinghai Zhang, 2015, The Journal of Biological Chemistry.

The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution*

Eric F. Johnson, C. Stout, J. Yano, 2004, Journal of Biological Chemistry.

Scaffold Oriented Synthesis. Part 1. Design, Preparation, and Biological Evaluation of Thienopyrazoles as Kinase Inhibitors.

J. R. Huth, D. Song, Eric F. Johnson, 2006 .

Deciphering Substrate Recognition by Drug-Metabolizing Cyto-chromes P450

Eric F. Johnson, 2003 .

The Structure of Human Cytochrome P450 2C9 Complexed with Flurbiprofen at 2.0-Å Resolution*

Eric F. Johnson, C. Stout, J. Yano, 2004, Journal of Biological Chemistry.

Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor

John E. Harlan, Ramesh Iyer, Yan Shi, 2011, Clinical Cancer Research.

Determinants of Cytochrome P450 2C8 Substrate Binding

Eric F. Johnson, C. Stout, J. Yano, 2008, Journal of Biological Chemistry.

Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 A resolution: evidence for an induced fit model of substrate binding.

C David Stout, Eric F. Johnson, D. Mansuy, 2003, Biochemistry.

An open conformation of mammalian cytochrome P450 2B4 at 1.6-Å resolution

James R. Halpert, Eric F. Johnson, J. Halpert, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Preclinical Characterization of ABT-348, a Kinase Inhibitor Targeting the Aurora, Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor, and Src Kinase Families

K. Glaser, S. Davidsen, C. Tse, 2012, Journal of Pharmacology and Experimental Therapeutics.

Human CYP 2 D 6 Structure 1 CRYSTAL STRUCTURE OF HUMAN CYTOCHROME P 450 2 D 6 WITH PRINOMASTAT BOUND

Eric F. Johnson, An Wang, C. David Stout, 2012 .

Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity.

Chaohong Sun, E. Olejniczak, Eric F. Johnson, 2006, Journal of medicinal chemistry.

Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors.

Eric F. Johnson, C. Abad-Zapatero, H. Sham, 2006, Journal of medicinal chemistry.

Synthesis and SAR of novel tricyclic quinoxalinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).

Eric F. Johnson, X. Liu, V. Giranda, 2009, Bioorganic & medicinal chemistry letters.

Enzymes in the Base Excision Repair Pathway as Targets for Small Molecule Mediated Therapeutics

Eric F. Johnson, R. Lloyd, A. McCullough, 2017 .

A Molecular Docking Strategy Identifies Eosin B as a Non-active Site Inhibitor of Protozoal Bifunctional Thymidylate Synthase-Dihydrofolate Reductase*

I. Coppens, J. Irwin, B. Shoichet, 2003, The Journal of Biological Chemistry.

Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt.

V. Stoll, Eric F. Johnson, X. Liu, 2007, Bioorganic & medicinal chemistry.

The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.

Eric F. Johnson, X. Liu, V. Giranda, 2008, Anticancer research.

Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks

Eric F. Johnson, X. Liu, V. Giranda, 2008, Molecular Cancer Research.

Structural Diversity of Eukaryotic Membrane Cytochrome P450s*

Eric F. Johnson, C. Stout, C. Stout, 2013, The Journal of Biological Chemistry.

Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.

V. Stoll, Eric F. Johnson, X. Liu, 2006, Bioorganic & medicinal chemistry letters.

PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow

S. C. Panchal, Mikkel A. Algire, P. Ellis, 2018, Molecular Cancer Research.

Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants.

Eric F. Johnson, D. Mansuy, M. Sari, 2004, Biochemistry.

Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization.

Xiaodong Zhang, Eric F. Johnson, J. Cashman, 2006, Journal of medicinal chemistry.

Structural Characterization of Human Cytochrome P450 2C19

Eric F. Johnson, C. Stout, S. Sansen, 2012, The Journal of Biological Chemistry.

Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases.

V. Stoll, Eric F. Johnson, N. Soni, 2009, Journal of medicinal chemistry.

1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel.

S. Davidsen, G. Gintant, Eric F. Johnson, 2007, Journal of medicinal chemistry.

Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605

S. Davidsen, Eric F. Johnson, N. Soni, 2009, BMC Cancer.

Conditions for Vigorous Growth on Sulfide and Reactor-Scale Cultivation Protocols for the Thermophilic Green Sulfur Bacterium Chlorobium tepidum

M. Ascano, Eric F. Johnson, B. Mukhopadhyay, 1999, Applied and Environmental Microbiology.

Investigation of biaryl heterocycles as inhibitors of Wee1 kinase.

K. Bromberg, Eric F. Johnson, N. Soni, 2019, Bioorganic & medicinal chemistry letters.

1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) Induces Phosphorylation of Eukaryotic Elongation Factor-2 (eEF2)

K. Glaser, U. Warrior, Eric F. Johnson, 2011, The Journal of Biological Chemistry.

Purification and crystallization of N-terminally truncated forms of microsomal cytochrome P450 2C5.

Eric F. Johnson, C. Stout, M. Wester, 2002, Methods in enzymology.

Differential regulation of human CYP4A genes by peroxisome proliferators and dexamethasone.

Eric F. Johnson, M. Hsu, U. Savas, 2003, Archives of biochemistry and biophysics.

Conditional regulation of the human CYP4X1 and CYP4Z1 genes.

Eric F. Johnson, D. Bell, K. Griffin, 2005, Archives of biochemistry and biophysics.

The Role of Nuclear Receptors in the Regulation of P450s and Other Genes by Peroxisome Proliferators

Eric F. Johnson, K. Griffin, M. Hsu, 1995 .

Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.

Eric F. Johnson, V. Giranda, Yan Luo, 2007, Biochemistry.

Crystal Structure of Human Microsomal P450 3A4

Eric F. Johnson, C. Stout, J. Yano, 2004 .

20-Hydroxyeicosatetraenoic Acid (HETE)-dependent Hypertension in Human Cytochrome P450 (CYP) 4A11 Transgenic Mice

Eric F. Johnson, F. Guengerich, J. Falck, 2016, The Journal of Biological Chemistry.

Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes

G. Besra, C. Vilchèze, W. Jacobs, 2017, Angewandte Chemie.

The X-ray Crystal Structure of the Human Monooxygenase Cytochrome P 450 3 A 5-Ritonavir Complex Reveals Active Site Differences between P 450 s 3 A 4 and 3 A 5

Eric F. Johnson, M. Hsu, U. Savas, 2017 .

Sulfaphenazole derivatives as tools for comparing cytochrome P450 2C5 and human cytochromes P450 2Cs: identification of a new high affinity substrate common to those enzymes.

Eric F. Johnson, D. Mansuy, P. Dansette, 2003, Biochemistry.

Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection

M. Manns, Eric F. Johnson, J. Pfeilschifter, 2008, The Journal of experimental medicine.

Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.

V. Stoll, Eric F. Johnson, X. Liu, 2006, Bioorganic & medicinal chemistry letters.

20-Hydroxyeicosatetraenoic Acid (HETE) Dependent Hypertension in Human Cytochrome P450 (CYP) 4A11 Transgenic Mice: Normalization of Blood Pressure by Sodium Restriction, Hydrochlorothiazide, or Blockade of the Type 1 Angiotensin II Receptor

Eric F. Johnson, F. Guengerich, J. Falck, 2016 .

Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling.

Eric F. Johnson, N. Soni, V. Giranda, 2008, Bioorganic & medicinal chemistry letters.

Ubiquitin-specific Cysteine Protease 2a (USP2a) Regulates the Stability of Aurora-A

Eric F. Johnson, X. Liu, V. Giranda, 2011, The Journal of Biological Chemistry.

Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase.

Eric F. Johnson, X. Liu, V. Giranda, 2006, Bioorganic & medicinal chemistry letters.

Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.

Eric F. Johnson, X. Liu, V. Giranda, 2006, Bioorganic & medicinal chemistry.

Coenzyme F420-Dependent Sulfite Reductase-Enabled Sulfite Detoxification and Use of Sulfite as a Sole Sulfur Source by Methanococcus maripaludis

Eric F. Johnson, B. Mukhopadhyay, 2008, Applied and Environmental Microbiology.

Rabbit Prostaglandin ω-Hydroxylase (CYP4A4): Gene Structure and Expression

Eric F. Johnson, K. Griffin, C. Palmer, 1993 .

Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.

Eric F. Johnson, X. Liu, V. Giranda, 2010, Journal of medicinal chemistry.

Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases.

S. Davidsen, Eric F. Johnson, J. Wilsbacher, 2010, Bioorganic & medicinal chemistry letters.

Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways

Eric F. Johnson, X. Liu, V. Giranda, 2009, Molecular Cancer Research.

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale

J. Garber, Eric F. Johnson, M. Robson, 2016, Future oncology.

ABT-869 a Multi-Targeted Receptor Tyrosine Kinase Inhibitor: Inhibition of FLT3 Phosphorylation and Signaling in Acute Myeloid Leukemia Running Title: ABT-869 Receptor Tyrosine Kinase Inhibitor in AML

K. Glaser, S. Davidsen, Eric F. Johnson, 2007 .

ABT-888 , an OrallyActive Poly ( ADP-Ribose ) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in PreclinicalTumorModels

Eric F. Johnson, T. DeWeese, X. Liu, 2007 .

Pyrazolo[3,4-d]pyrimidines as potent inhibitors of the insulin-like growth factor receptor (IGF-IR).

S. Davidsen, Eric F. Johnson, J. Wilsbacher, 2007, Bioorganic & medicinal chemistry letters.

Scaffold oriented synthesis. Part 4: design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing heterocycle forming and multicomponent reactions.

Eric F. Johnson, I. Akritopoulou‐Zanze, P. Kovar, 2011, Bioorganic & medicinal chemistry letters.

Azaindole-Based Inhibitors of Cdc7 Kinase: Impact of the Pre-DFG Residue, Val 195.

K. Swinger, Eric F. Johnson, N. Soni, 2013, ACS medicinal chemistry letters.

Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer.

P. Ellis, Eric F. Johnson, X. Liu, 2012, Bioorganic & medicinal chemistry.

ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

Eric F. Johnson, T. DeWeese, X. Liu, 2007, Clinical Cancer Research.

Aminopyrimidinone cdc7 kinase inhibitors.

Eric F. Johnson, N. Soni, J. Miyashiro, 2012, Bioorganic & medicinal chemistry letters.

Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.

Eric F. Johnson, X. Liu, V. Giranda, 2008, Bioorganic & medicinal chemistry.

Synthesis and SAR of novel, potent and orally bioavailable benzimidazole inhibitors of poly(ADP-ribose) polymerase (PARP) with a quaternary methylene-amino substituent.

Eric F. Johnson, X. Liu, V. Giranda, 2008, Bioorganic & medicinal chemistry letters.

2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.

Eric F. Johnson, R. Dixon, D. Borhani, 2010, Bioorganic & medicinal chemistry letters.

Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.

Eric F. Johnson, X. Liu, V. Giranda, 2009, Journal of medicinal chemistry.

Adenosine-anchored triphosphate subsite probing: distinguishing between HER-2 and HER-4 tyrosine protein kinases.

K. Anderson, Eric F. Johnson, D. Austin, 2003, Bioorganic & medicinal chemistry letters.

Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.

Zhiqin Ji, Irini Akritopoulou-Zanze, K. Glaser, 2008, Bioorganic & medicinal chemistry letters.

The cytochrome P450 supergene family: genetic organization and function

Eric F. Johnson, K. Griffin, 2000 .

A New Type of Sulfite Reductase, a Novel Coenzyme F420-dependent Enzyme, from the Methanarchaeon Methanocaldococcus jannaschii*

Eric F. Johnson, B. Mukhopadhyay, 2005, Journal of Biological Chemistry.

A Novel Coenzyme F420 Dependent Sulfite Reductase and a Small Sulfite Reductase in Methanogenic Archaea

Eric F. Johnson, B. Mukhopadhyay, 2008 .

Coenzyme F420-Dependent Sulfite Reductase-Enabled Sulfite Detoxification and Use of Sulfite as a Sole Sulfur Source by Methanococcus maripaludis

Eric F. Johnson, B. Mukhopadhyay, 2008, Applied and Environmental Microbiology.

Reactor-Scale Cultivation of the Hyperthermophilic MethanarchaeonMethanococcus jannaschii to High Cell Densities

Eric F. Johnson, B. Mukhopadhyay, R. Wolfe, 1999, Applied and Environmental Microbiology.

Noncovalent interactions dominate dynamic heme distortion in cytochrome P450 4B1

Eric F. Johnson, M. Hsu, J. Hackett, 2018, The Journal of Biological Chemistry.

The Crystal Structure of Cytochrome P450 4B1 (CYP4B1) Monooxygenase Complexed with Octane Discloses Several Structural Adaptations for ω-Hydroxylation*♦

Eric F. Johnson, A. Rettie, M. Hsu, 2017, The Journal of Biological Chemistry.

Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.

V. Stoll, Eric F. Johnson, X. Liu, 2006, Bioorganic & medicinal chemistry letters.

Bilirubin Production from Erythroid Sources

Eric F. Johnson, U. Muller-eberhard, 1975 .

Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers.

Eric F. Johnson, X. Liu, V. Giranda, 2006, Bioorganic & medicinal chemistry letters.

Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo

Yan Shi, V. Stoll, Eric F. Johnson, 2005, Molecular Cancer Therapeutics.

Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain

Eric F. Johnson, C. Stout, I. Pikuleva, 2008, Proceedings of the National Academy of Sciences.

Inward facing conformations of the MetNI methionine ABC transporter: Implications for the mechanism of transinhibition

T. Yeates, D. Rees, Eric F. Johnson, 2012, Protein science : a publication of the Protein Society.

The High-Affinity E. coli Methionine ABC Transporter: Structure and Allosteric Regulation

D. Rees, Eric F. Johnson, Allen T. Lee, 2008, Science.

The role of cytochrome P-450 forms in 2-aminoanthracene and benz[α]pyrene mutagenesis

Eric F. Johnson, U. Muller-eberhard, R. L. Norman, 1979 .

Engineering Microsomal Cytochrome P450 2C5 to Be a Soluble, Monomeric Enzyme

Eric F. Johnson, J. Cosme, 2000, The Journal of Biological Chemistry.

Mapping Determinants of the Substrate Specificities of P450s by Site-Directed Mutagenesis

Eric F. Johnson, T. Richardson, M. Hsu, 1995 .

The 2002 Bernard B. Brodie Award lecture: deciphering substrate recognition by drug-metabolizing cytochromes P450.

Eric F. Johnson, Eric F Johnson, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Correlating Structure and Function of Drug-Metabolizing Enzymes: Progress and Ongoing Challenges

Eric F. Johnson, M. Desai, J. Laurence, 2014, Drug Metabolism and Disposition.

Abstract A239: Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora, VEGFR/PDGFR, and SRC kinase families.

K. Glaser, S. Davidsen, C. Tse, 2011 .

ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.

Yujia Dai, K. Glaser, S. Davidsen, 2007, Blood.

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

K. Glaser, S. Davidsen, Eric F. Johnson, 2005, Molecular Cancer Therapeutics.

Novel Sequence Determinants in Peroxisome Proliferator Signaling (*)

Eric F. Johnson, K. Griffin, M. Hsu, 1995, The Journal of Biological Chemistry.

Rationale for the combination of veliparib with platinum-based chemotherapy.

Eric F. Johnson, T. Penning, E. DiGiammarino, 2015 .

246 PARP inhibitors trap PARP1 onto damaged DNA via catalytic inhibition and not by an allosteric mechanism

Eric F. Johnson, E. DiGiammarino, L. Solomon, 2014 .

Abstract 2734: Veliparib (ABT-888) potentiates the cytotoxic activity of DNA alkylating agents by trapping PARP onto damaged chromatin

P. Ellis, Eric F. Johnson, G. Fang, 2014 .

Crystal Structure of CYP 24 A 1 , a Mitochondrial Cytochrome P 450 Involved in Vitamin D Metabolism

Eric F. Johnson, D. Goodin, C. Stout, 2010 .

Structural Characterization of the Complex between α-Naphthoflavone and Human Cytochrome P450 1B1*

Eric F. Johnson, C. Stout, U. Savas, 2010, The Journal of Biological Chemistry.

Single mutations change CYP2F3 from a dehydrogenase of 3-methylindole to an oxygenase.

Eric F. Johnson, Hao Sun, C. Reilly, 2008, Biochemistry.

Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin and phenobarbital on the occurrence and distribution of four cytochrome P-450 isozymes in rabbit kidney, lung, and liver.

Eric F. Johnson, J. Dees, U. Muller-eberhard, 1982, Cancer research.

Genistein, Resveratrol, and 5-Aminoimidazole-4-carboxamide-1-β-d-ribofuranoside Induce Cytochrome P450 4F2 Expression through an AMP-Activated Protein Kinase-Dependent Pathway

Eric F. Johnson, M. Hsu, J. Lasker, 2011, Journal of Pharmacology and Experimental Therapeutics.

Regulation of Human Cytochrome P450 4F2 Expression by Sterol Regulatory Element-binding Protein and Lovastatin*

Eric F. Johnson, K. Griffin, M. Hsu, 2007, Journal of Biological Chemistry.

Heme–thiolate sulfenylation of human cytochrome P450 4A11 functions as a redox switch for catalytic inhibition

A. Pozzi, Eric F. Johnson, F. Guengerich, 2017, The Journal of Biological Chemistry.

Structures of Cytochrome P450 Enzymes

T. Poulos, Eric F. Johnson, 2015 .

Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases.

Scott A. Erickson, S. Davidsen, K. Swinger, 2010, Bioorganic & medicinal chemistry letters.

Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.

A. Vasudevan, Eric F. Johnson, V. Giranda, 2012, Bioorganic & medicinal chemistry letters.

Opposing Roles of Peroxisome Proliferator-activated Receptor α and Growth Hormone in the Regulation of CYP4A11 Expression in a Transgenic Mouse Model*

R. Tukey, Eric F. Johnson, M. Hsu, 2009, The Journal of Biological Chemistry.

Regulation of P450 4A expression by peroxisome proliferator activated receptors.

Eric F. Johnson, K. Griffin, M. Hsu, 2002, Toxicology.

Human Cytochrome P450 Family 4 Enzymes: Function, Genetic Variation and Regulation

Eric F. Johnson, K. Griffin, M. Hsu, 2007, Drug metabolism reviews.

Structural diversity of human xenobiotic-metabolizing cytochrome P450 monooxygenases.

C David Stout, Eric F. Johnson, C. Stout, 2005, Biochemical and biophysical research communications.

CYP2C8 Exists as a Dimer in Natural Membranes

Eric F. Johnson, B. Kemper, Eric F Johnson, 2010, Drug Metabolism and Disposition.

Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents.

P. Ellis, Eric F. Johnson, N. Soni, 2009, Journal of medicinal chemistry.

The CYP4A Isoforms Hydroxylate Epoxyeicosatrienoic Acids to Form High Affinity Peroxisome Proliferator-activated Receptor Ligands*

Eric F. Johnson, J. Falck, J. Capdevila, 2002, The Journal of Biological Chemistry.

Mechanistic characterization of Toxoplasma gondii thymidylate synthase (TS-DHFR)-dihydrofolate reductase. Evidence for a TS intermediate and TS half-sites reactivity.

W. Hinz, F. Maley, K. Anderson, 2002, The Journal of biological chemistry.

Crystal structure of CYP24A1, a mitochondrial cytochrome P450 involved in vitamin D metabolism.

Eric F. Johnson, D. Goodin, C. Stout, 2010, Journal of molecular biology.

Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 A resolution: evidence for multiple substrate binding modes.

C David Stout, Eric F. Johnson, D. Mansuy, 2003, Biochemistry.

Explicit water near the catalytic I helix Thr in the predicted solution structure of CYP2A4.

T. Darden, L. Pedersen, L. Perera, 2003, Biophysical journal.

Active-site differences between substrate-free and ritonavir-bound cytochrome P450 (CYP) 3A5 reveal plasticity differences between CYP3A5 and CYP3A4

Eric F. Johnson, M. Hsu, 2019, The Journal of Biological Chemistry.

Structures of Eukaryotic Cytochrome P450 Enzymes

Eric F. Johnson, C. Wachenfeldt, 1995 .

Structural insight into the altered substrate specificity of human cytochrome P450 2A6 mutants.

Eric F. Johnson, C. Stout, M. Hsu, 2007, Archives of biochemistry and biophysics.

5-Aminoimidazole-4-carboxyamide-ribonucleoside (AICAR)-Stimulated Hepatic Expression of Cyp4a10, Cyp4a14, Cyp4a31, and Other Peroxisome Proliferator-Activated Receptor α-Responsive Mouse Genes Is AICAR 5′-Monophosphate-Dependent and AMP-Activated Protein Kinase-Independent

Eric F. Johnson, Namandjé N. Bumpus, 2011, Journal of Pharmacology and Experimental Therapeutics.

Crystal Structure of Human Cytochrome P450 2D6 with Prinomastat Bound*

Eric F. Johnson, C. Stout, M. Hsu, 2012, The Journal of Biological Chemistry.

Multiple Forms of Rabbit Cytochrome P450: Comparison of Chemical Physical, Immunological and Biocatalytic Properties

R. Tukey, T. Kronbach, Eric F. Johnson, 1991 .

Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug–Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors

J. Pandit, K. Parris, Eric F. Johnson, 2015, Journal of medicinal chemistry.

The X-Ray Crystal Structure of the Human Mono-Oxygenase Cytochrome P450 3A5-Ritonavir Complex Reveals Active Site Differences between P450s 3A4 and 3A5

Eric F. Johnson, M. Hsu, U. Savas, 2018, Molecular Pharmacology.

Mechanistic Dissection of PARP 1 Trapping and the Impacton InVivo TolerabilityandEf fi cacyofPARP Inhibitors

Eric F. Johnson, J. Wilsbacher, E. DiGiammarino, 2015 .

Cancer Therapy : Preclinical Iniparib Nonselectively Modi fi es Cysteine-Containing Proteins in TumorCells and IsNot a Bona Fide PARP Inhibitor

P. Ellis, Eric F. Johnson, N. Soni, 2012 .

Use of complementary cation and anion heavy-atom salt derivatives to solve the structure of cytochrome P450 46A1

Eric F. Johnson, C. Stout, I. Pikuleva, 2008, Acta crystallographica. Section D, Biological crystallography.

Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality

K. Parris, Eric F. Johnson, K. Atchison, 2016, Journal of medicinal chemistry.

Complete Genome Sequence of Desulfurococcus fermentans, a Hyperthermophilic Cellulolytic Crenarchaeon Isolated from a Freshwater Hot Spring in Kamchatka, Russia

N. Kyrpides, T. Lowe, S. Lucas, 2012, Journal of bacteriology.

Author Index to Volume 228, April-June 1985

F. Bloom, K. Arrow, P. Anderson, 1985, Science.

DIAZEPAM METABOLISM BY CDNA-Expressed Human 2 C P 450 S Identification of P 4502 C 18 and P 4502 C 19 as Low KM Diazepam N-Demethylases

Eric F. Johnson, T. Richardson, F. Jung, 1997 .

44 – MULTIPLE DETERMINANTS FOR SUBSTRATE SPECIFICITIES IN CYTOCHROME P450 ISOZYMES

T. Kronbach, Eric F. Johnson, 1990 .

Characterization of the multiplicity of drug-metabolizing enzymes: observations on cytochrome P-450 diversity

R. Tukey, Eric F. Johnson, J. Raucy, 1984 .

CYTOCHROME P-450 FORM 4, A MAJOR DETERMINANT OF 2-AMINOANTHRACENE MUTAGENESIS

Eric F. Johnson, U. Muller-eberhard, R. L. Norman, 1980 .

CONTRASTING PROPERTIES OF MICROSOMAL CYTOCHROME P-450: CHARACTERIZATION OF A CONSTITUTIVE FORM OF THE CYTOCHROME

Eric F. Johnson, 1980 .

Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer.

Eric F. Johnson, E. Vokes, S. Feigenberg, 2021, Lung Cancer.

Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.

V. Stoll, G. Gintant, Eric F. Johnson, 2007, Journal of medicinal chemistry.

Structure of Mammalian Cytochrome P450 2B4 Complexed with 4-(4-Chlorophenyl)imidazole at 1.9-Å Resolution

Eric F. Johnson, J. Halpert, C. Stout, 2004, Journal of Biological Chemistry.

CYP 2 C 8 Exists as a Dimer in Natural Membranes

Eric F. Johnson, B. Kemper, G. Hu, 2010 .

Cytochrome P 450 2 C 8 Exists as a Dimer in Natural Membranes

Eric F. Johnson, B. Kemper, G. Hu, 2010 .

Structure of mammalian cytochrome P450 2B4

Eric F. Johnson, J. Halpert, C. Stout, 2000 .

Probing Electrostatic Channeling in Protozoal Bifunctional Thymidylate Synthase-Dihydrofolate Reductase Using Site-directed Mutagenesis*

K. Anderson, C. Atreya, Eric F. Johnson, 2003, Journal of Biological Chemistry.

Pyrimidine-based tricyclic molecules as potent and orally efficacious inhibitors of wee1 kinase.

K. Bromberg, Eric F. Johnson, N. Soni, 2015, ACS medicinal chemistry letters.

Scaffold oriented synthesis. Part 1: Design, preparation, and biological evaluation of thienopyrazoles as kinase inhibitors.

J. R. Huth, D. Song, Eric F. Johnson, 2006, Bioorganic & medicinal chemistry letters.

1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) Induces Phosphorylation of Eukaryotic Elongation Factor-2 (eEF2)

K. Glaser, U. Warrior, Eric F. Johnson, 2011, The Journal of Biological Chemistry.

Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases.

Scott A. Erickson, S. Davidsen, Eric F. Johnson, 2009, Bioorganic & medicinal chemistry letters.

Utilizing CYP2D6 and BACE1 Structure Complexes to Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors

K. Parris, Eric F. Johnson, S. Sakya, 2015 .

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

S. Fesik, Eric F. Johnson, S. Rosenberg, 2008, Cancer research.

Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes

G. Besra, W. Jacobs, Eric F. Johnson, 2017, Angewandte Chemie.

Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.

Eric F. Johnson, X. Liu, V. Giranda, 2009, Journal of medicinal chemistry.

Resolution of Multiple Forms of Rabbit Liver Cytochrome P-450

Eric F. Johnson, U. Muller-eberhard, 1977 .

Amino Acid Residues Critical for Differential Inhibition of CYP 2 B 4 , CYP 2 B 5 , and CYP 2 B 1 by Phenylimidazoles

Eric F. Johnson, J. Halpert, M. Spatzenegger, 2001 .

THE STRUCTURE OF MICROSOMAL CYTOCHROME P450 2C5: A STEROID AND DRUG METABOLIZING ENZYME

Eric F. Johnson, M. R. Wester, C. David Stout, 2002, Endocrine research.

Analyzing binding of N-terminal truncated, microsomal cytochrome P450s to membranes.

Eric F. Johnson, J. Cosme, 2002, Methods in enzymology.

Pyrimidine-based tricyclic molecules as potent and orally efficacious inhibitors of wee1 kinase.

K. Bromberg, Eric F. Johnson, N. Soni, 2015, ACS medicinal chemistry letters.

ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.

K. Glaser, S. Davidsen, Eric F. Johnson, 2007, Blood.